Expression of CD147 After Neoadjuvant Chemotherapy and Its Relationship with Prognosis in Patients with Triple Negative Breast Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2022 Jun 15

PMID 35702119

Authors

Wei Zhang

Hui Liu

Junjie Jiang

Yunyun Yang

Wenjie Wang

Zhengyan Jia

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC) has rapid development and a worse prognosis, without special treatment. It is necessary to explore targeted treatment.

Objective: To explore the significance of CD147 and matrix metalloproteinase-9 (MMP-9) in TNBC and their influence on prognosis.

Methods: 81 TNBC patients admitted to our hospital and 86 healthy individuals undergoing physical examination from August 2014 to August 2016 were included. The concentrations of serum CD147 and MMP-9, their diagnostic value, and their relationship with clinicopathologic features were analyzed. A 3-year follow-up visit was conducted to assess the prognostic effect of CD147. Its effect on the biologic behavior of breast cancer cells was also determined.

Results: Higher serum CD147 and MMP-9 levels were found in TNBC patients than healthy individuals (P<0.05). CD147 and MMP-9 were closely related to the pathologic stage, metastasis, and differentiation of the tumors (P<0.05). A positive correlation between CD147 and MMP-9 was detected before chemotherapy (n=127, r=0.609, P<0.01), with similar expression rates of CD147 (76.9%) and MMP-9 (80.67%) (P>0.05). The 2 markers were independent risk factors for poor prognosis in TNBC (P=0.023; P=0.015), and increased CD147/MMP-9 expression was significantly related to treatment failure. After chemotherapy, the expression of CD147 in TNBC patients decreased, and higher expression predicted death (P<0.05). The sensitivity and specificity of CD147 for death in 3-year follow-up were 76.92% and 88.89%, and the expression of CD147 in breast cancer cells was increased (P<0.001). Interfering with CD147 can decrease the proliferation and invasion of breast cancer cells and increase apoptotic rate (P<0.05).

Conclusion: CD147 can promote the proliferation and invasion of breast cancer cells, which underlines its value in the diagnosis and treatment of TNBC.

Citing Articles

Radioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer.

Ma X, Liu T, Guo R, Zhou W, Yao Y, Wen D Eur J Nucl Med Mol Imaging. 2024; 52(4):1406-1421.

PMID: 39549046 DOI: 10.1007/s00259-024-06985-3.

I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies.

Ma X, Liu T, Ren Y, Ma X, Yao Y, Hou X Acta Pharmacol Sin. 2023; 45(2):436-448.

PMID: 37749238 PMC: 10789738. DOI: 10.1038/s41401-023-01162-y.

Expression patterns of cluster of differentiation 147 impact the prognosis of hepatocellular carcinoma.

Xu Y, He H, Wu P, Li W World J Gastrointest Oncol. 2023; 15(8):1412-1423.

PMID: 37663949 PMC: 10473926. DOI: 10.4251/wjgo.v15.i8.1412.

References

Gao Y, Wang J, Zhou Y, Sheng S, Qian S, Huo X . Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Sci Rep. 2018; 8(1):2732. PMC: 5807317. DOI: 10.1038/s41598-018-21048-y. View

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Zheng H, Gong B . CD147 expression was positively linked to aggressiveness and worse prognosis of gastric cancer: a meta and bioinformatics analysis. Oncotarget. 2017; 8(52):90358-90370. PMC: 5685756. DOI: 10.18632/oncotarget.20089. View

Shimelis H, LaDuca H, Hu C, Hart S, Na J, Thomas A . Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst. 2018; 110(8):855-862. PMC: 6093350. DOI: 10.1093/jnci/djy106. View

Shufelt C, Merz C, Pettinger M, Choi L, Chlebowski R, Crandall C . Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. Menopause. 2018; 25(9):985-991. PMC: 6103839. DOI: 10.1097/GME.0000000000001115. View

McDaniel J, Varley K, Gertz J, Savic D, Roberts B, Bailey S . Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget. 2016; 8(5):8226-8238. PMC: 5352396. DOI: 10.18632/oncotarget.14153. View

Ji Y, Li J, Li P, Wang L, Yang H, Jiang G . C/EBPβ Promotion of MMP3-Dependent Tumor Cell Invasion and Association with Metastasis in Colorectal Cancer. Genet Test Mol Biomarkers. 2017; 22(1):5-10. DOI: 10.1089/gtmb.2017.0113. View

Patel N, Weekes D, Drosopoulos K, Gazinska P, Noel E, Rashid M . Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer. Nat Commun. 2018; 9(1):1044. PMC: 5849766. DOI: 10.1038/s41467-018-03283-z. View

10.

Zhou Y, Wu B, Li J, Nan G, Jiang J, Chen Z . Rab22a enhances CD147 recycling and is required for lung cancer cell migration and invasion. Exp Cell Res. 2017; 357(1):9-16. DOI: 10.1016/j.yexcr.2017.04.020. View

11.

Liu J, Liu Q, Wang Y, Liu M, Qi Y, Gao J . Co‑expression of Lewis y antigen and CD147 in epithelial ovarian cancer is correlated with malignant progression and poor prognosis. Int J Mol Med. 2019; 43(4):1687-1698. PMC: 6414171. DOI: 10.3892/ijmm.2019.4103. View

12.

Malvia S, Bagadi S, Dubey U, Saxena S . Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 2017; 13(4):289-295. DOI: 10.1111/ajco.12661. View

13.

Suzuki S, Toyoma S, Tsuji T, Kawasaki Y, Yamada T . CD147 mediates transforming growth factor-β1-induced epithelial-mesenchymal transition and cell invasion in squamous cell carcinoma of the tongue. Exp Ther Med. 2019; 17(4):2855-2860. PMC: 6425230. DOI: 10.3892/etm.2019.7230. View

14.

Dana P, Saisomboon S, Kariya R, Okada S, Obchoei S, Sawanyawisuth K . CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion. Cell Oncol (Dordr). 2019; 43(2):211-222. DOI: 10.1007/s13402-019-00479-3. View

15.

Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A . Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017; 3(10):1378-1385. PMC: 5710508. DOI: 10.1001/jamaoncol.2017.1007. View

16.

von Ungern-Sternberg S, Zernecke A, Seizer P . Extracellular Matrix Metalloproteinase Inducer EMMPRIN (CD147) in Cardiovascular Disease. Int J Mol Sci. 2018; 19(2). PMC: 5855729. DOI: 10.3390/ijms19020507. View

17.

Jitariu A, Cimpean A, Ribatti D, Raica M . Triple negative breast cancer: the kiss of death. Oncotarget. 2017; 8(28):46652-46662. PMC: 5542300. DOI: 10.18632/oncotarget.16938. View

18.

Guo W, Abudumijiti H, Xu L, Hasim A . CD147 promotes cervical cancer migration and invasion by up-regulating fatty acid synthase expression. Int J Clin Exp Pathol. 2020; 12(12):4280-4288. PMC: 6949868. View

19.

Lee A, Djamgoz M . Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2017; 62:110-122. DOI: 10.1016/j.ctrv.2017.11.003. View

20.

Zhang X, Tian T, Zhang X, Liu C, Fang X . Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer. Oncotarget. 2017; 8(23):37673-37680. PMC: 5514939. DOI: 10.18632/oncotarget.16948. View